ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anbenitamab

Also written as “KN026”, “KN026 combination” and “Recombinant Humanized Bispecific antibody against HER2,KN026”.

Its studies are mostly in Breast Neoplasms · Stomach Neoplasms, led by 2 companies.

Drug pageAnbenitamab: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 22, 201912 company-led studies, 7 open or runningLicense: Alphamab → CSPC (JMT-Bio), Aug 2021Next primary completion: Dec 16, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology61 open or runningphase 2since Apr 22, 2019Aug 3, 2018none ahead
CSPC Pharmaceutical Groupits history only66 open or runningphase 3since Jun 14, 2022Jun 14, 2022Dec 16, 2026phase 3 · NCT06747338
  • Named in CSPC Pharmaceutical Group’s own pipeline as anbenitamab (KN026), phase 4, as of Aug 20, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Alphamab Oncology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2018First study: phase 1 study in Breast NeoplasmsFirst studyNCT03619681 · 63 enrolled · China
  2. Feb 18, 2019Phase 1 study in Breast NeoplasmsNCT03847168 · 22 enrolled · United States
  3. Apr 22, 2019Phase 2 study in Gastric/Gastroesophageal Junction CancerNCT03925974 · 45 enrolled · China
  4. Nov 1, 2019Phase 2 study in Breast NeoplasmsNCT04165993 · 68 enrolled · China
  5. Aug 18, 2020Phase 2 study in HER2-positive Solid TumorsNCT04521179 · 102 enrolled · China
  6. Dec 19, 2020Named anbenitamabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, KN026
  7. May 6, 2021Phase 2 study in Breast NeoplasmsNCT04881929 · 30 enrolled · China
  8. Aug 23, 2021CSPC (JMT-Bio) licensed it from AlphamabLicenseMainland China, in breast and gastric cancer · agreed · Alphamab Oncology (HKEX announcement)

TargetBeta

“An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HE…”NCIt, read by Claude
“An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2;”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 6 Alphamab Oncology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04881929Breast Neoplasms · China2UNKNOWNNov 15, 202230
NCT04521179HER2-positive Solid Tumors · China2CompletedJan 12, 2022102
NCT04165993Breast Neoplasms · China2Active, not recruitingMay 27, 202168
NCT03925974Gastric/Gastroesophageal Junction Cancer · China2CompletedMay 31, 202245
NCT03847168Breast Neoplasms · United States1UNKNOWNDec 31, 202222
NCT03619681Breast Neoplasms · China1CompletedJun 30, 202263

How it is read

Names in the registry

  • “KN026”, 7 entries
  • “KN026 combination”, 2 entries
  • “Recombinant Humanized Bispecific antibody against HER2,KN026”, 1 entry
  • “KN026 10 mg/kg QW”, 1 entry
  • “KN026 20 mg/kg Q2W”, 1 entry

Codes read as this program: KN026.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.